tiprankstipranks
Trending News
More News >

Fulgent Genetics Reports Strong Q1 2025 Financial Results

Story Highlights
  • Fulgent Genetics reported a 16% growth in core revenue for Q1 2025, totaling $73.5 million.
  • Despite a GAAP loss, Fulgent achieved a non-GAAP income of $1.2 million and reiterated its 2025 revenue guidance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Confident Investing Starts Here:

Fulgent Genetics ( (FLGT) ) has shared an update.

On May 2, 2025, Fulgent Genetics reported its financial results for the first quarter of 2025, highlighting a 16% year-over-year growth in core revenue, amounting to $73.5 million. Despite a GAAP loss of $11.5 million, the company achieved a non-GAAP income of $1.2 million. Fulgent reiterated its full-year 2025 core revenue guidance of $310 million and ended the quarter with $814.6 million in cash and investments. The company repurchased approximately 516,000 shares at a cost of $8.7 million. CEO Ming Hsieh expressed satisfaction with the results and the momentum in 2025, while CFO Paul Kim noted the strong start to the year with growth across all core business areas.

Spark’s Take on FLGT Stock

According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.

Fulgent Genetics scores moderately due to financial challenges marked by declining revenues and profitability, which impact liquidity. While the balance sheet is strong, the valuation remains unattractive with a negative P/E ratio. Technical analysis shows limited momentum. However, the earnings call provided some optimism with strong revenue growth and promising strategic partnerships.

To see Spark’s full report on FLGT stock, click here.

More about Fulgent Genetics

Fulgent Genetics, Inc. is a technology-based company with a well-established laboratory services business and a therapeutic development business. The company provides technical laboratory and testing services, along with professional interpretation of laboratory results by licensed physicians. Fulgent is also focused on developing drug candidates for treating various cancers using a novel nanoencapsulation and targeted therapy platform, aiming to transform into a fully integrated precision medicine company.

YTD Price Performance: -6.35%

Average Trading Volume: 468,284

Technical Sentiment Signal: Buy

Current Market Cap: $532.4M

See more insights into FLGT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App